Patents by Inventor Thierry Ragot

Thierry Ragot has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Defective recombinant adenoviruses expressing cytokines for antitumor treatment
    Patent number: 7306793
    Abstract: A recombinant nucleic acid used for the production of a defective adenovirus containing an inserted sequence coding for a cytokine under the control of a promoter in the genomic sequence of the recombinant adenovirus. This recombinant adenovirus is useful in the preparation of anti-tumoral drugs which can be directly injected into the tumor of the host.
    Type: Grant
    Filed: September 13, 2004
    Date of Patent: December 11, 2007
    Assignees: Centre National de la Recherche Scientifique, Institut Gustave Roussy
    Inventors: Hédi Mohamed Haddada, Thierry Ragot, Michel Perricaudet
  • Defective recombinant adenoviruses expressing cytokines for antitumor treatment
    Publication number: 20050048031
    Abstract: Recombinant nucleic acid for use in the production of a defective adenovirus containing an inserted sequence coding for a cytokine under the control of a promoter in the genomic sequence of the recombinant adenovirus. Said recombinant adenovirus is useful in the preparation of anti-tumoral drugs capable of being directly injected into the tumor of the host.
    Type: Application
    Filed: September 13, 2004
    Publication date: March 3, 2005
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT GUSTAVE ROUSSY
    Inventors: Hedi Haddada, Thierry Ragot, Michel Perricaudet
  • Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors
    Publication number: 20040265273
    Abstract: The present invention relates to gene therapy for the treatment of tumors. The invention more particularly relates to introduction of a gene encoding an anti-angiogenic factor into cells of a tumor, for example with a defective adenovirus vector, to inhibit growth or metastasis, or both, of the tumor. In a specific embodiment, delivery of a defective adenovirus that expresses the amino terminal fragment of urokinase (ATF) inhibited growth and metastasis of tumors. These effects were correlated with a remarkable inhibition of neovascularization within, and at the immediate vicinity of, the injection site. Delivery of a defective adenovirus vector that expresses kringles 1 to 3 of angiostatin inhibited tumor growth and tumorigenicity, and induced apoptosis of tumor cells. The invention further provides viral vectors for use in the methods of the invention.
    Type: Application
    Filed: October 27, 2003
    Publication date: December 30, 2004
    Inventors: Hong Li, He Lu, Frank Griscelli, Paule Opolon, Claudine Soria, Thierry Ragot, Yves Legrand, Jeannette Soria, Christelle Mabilat, Michel Perricaudet, Patrice Yeh
  • Defective recombinant adenoviruses expressing cytokines for antitumor treatment
    Patent number: 6811774
    Abstract: A recombinant nucleic acid used for the production of a defective adenovirus containing an inserted sequence coding for a cytokine under the control of a promoter in the genomic sequence of the recombinant adenovirus. This recombinant adenovirus is useful in the preparation of anti-tumoral drugs which can be directly injected into the tumor of the host.
    Type: Grant
    Filed: December 3, 1998
    Date of Patent: November 2, 2004
    Assignees: Centre National de la Recherche Scientifique, Institut Gustave Roussy
    Inventors: Hedi Mohamed Haddada, Thierry Ragot, Michel Perricaudet
  • Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors
    Patent number: 6638502
    Abstract: The present invention relates to gene therapy for the treatment of tumors. The invention more particularly relates to introduction of a gene encoding an anti-angiogenic factor into cells of a tumor, for example with a defective adenovirus vector, to inhibit growth or metastasis, or both, of the tumor. In a specific embodiment, delivery of a defective adenovirus that expresses the amino terminal fragment of urokinase (ATF) inhibited growth and metastasis of tumors. These effects were correlated with a remarkable inhibition of neovascularization within, and at the immediate vicinity of, the injection site. Delivery of a defective adenovirus vector that expresses kringles 1 to 3 of angiostatin inhibited tumor growth and tumorigenicity, and induced apoptosis of tumor cells. The invention further provides viral vectors for use in the methods of the invention.
    Type: Grant
    Filed: June 29, 2000
    Date of Patent: October 28, 2003
    Assignee: Gencell SAS
    Inventors: Hong Li, He Lu, Frank Griscelli, Paule Opolon, Claudine Soria, Thierry Ragot, Yves Legrand, Jeannette Soria, Christelle Mabilat, Michel Perricaudet, Patrice Yeh
  • DEFECTIVE RECOMBINANT ADENOVIRUSES EXPRESSING CYTOKINES FOR ANTITUMOR TREATMENT
    Publication number: 20020031499
    Abstract: Recombinant nucleic acid for use in the production of a defective adenovirus containing an inserted sequence coding for a cytokine under the control of a promotor in the genomic sequence of the recombinant adenovirus. Said recombinant adenovirus is useful in the preparation of anti-tumoral drugs capable of being directly injected into the tumour of the host.
    Type: Application
    Filed: December 3, 1998
    Publication date: March 14, 2002
    Inventors: HEDI HADDADA, THIERRY RAGOT, MICHEL PERRICAUDET